PCSK9 and familial hyperaldosteronism: Verve Therapeutics is developing a liver-directed therapy for FH through disruption of PCSK9, using a base editor to avoid the undesirable on-target effects induced by DSB as well as LNPs to transiently deliver the base editor as mRNA.